Loading...
Market
How many new targeted oncology drugs will Daiichi Sankyo get approved by December 31, 2025?
2
Resolution / Starting Odds
0 • 25%
1 • 25%
2 • 25%
3 or more • 25%
FDA and EMA announcements or press releases
Story
Daiichi Sankyo-Merck's Patritumab Deruxtecan Meets Main Goal in Phase 3 Trial
Sep 17, 2024, 10:04 AM
Daiichi Sankyo and Merck have announced that their cancer drug, patritumab deruxtecan, has met the main goal in a Phase 3 late-stage trial for certain patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). The drug, described as a 'guided-missile' cancer treatment, shows promise in targeting specific cancer cells. This development comes as Daiichi Sankyo aims to advance its next generation of targeted oncology drugs, potentially without the need for a partner.
View original story
Similar markets
None • 25%
One • 25%
Two • 25%
Three or more • 25%
None • 25%
One • 25%
Two • 25%
Three or more • 25%
None • 25%
One • 25%
Two • 25%
Three or more • 25%
0 new indications • 33%
1 new indication • 33%
2 or more new indications • 34%
None • 25%
One • 25%
Two • 25%
Three or more • 25%
0-5 • 25%
6-10 • 25%
11-15 • 25%
16 or more • 25%
0 • 25%
1 • 25%
2 • 25%
3 or more • 25%
None • 25%
One • 25%
Two • 25%
Three or more • 25%
None • 25%
One • 25%
Two • 25%
Three or more • 25%
None • 25%
1 • 25%
2 • 25%
3 or more • 25%
None • 25%
1 additional indication • 25%
2 additional indications • 25%
3 or more additional indications • 25%
Afami-cel • 25%
Cosibelimab • 25%
Adagrasib-Cetuximab • 25%
Other • 25%